目的 探討四磨湯口服液治療小兒功能性消化不良（FD）的臨床效果。方法 收集宜川縣人民醫(yī)院2016年1月-2016年12月收治的小兒FD患者120例，按照隨機(jī)數(shù)字表法分為觀察組和對(duì)照組，每組60例，兩組均給予常規(guī)治療，觀察組在常規(guī)治療基礎(chǔ)上給予四磨湯口服液治療，1~3歲一次3~5 mL，一日3次，療程2 d；4~12歲一次10 mL，一日3次，療程3~5 d；對(duì)照組在常規(guī)治療基礎(chǔ)上給予安慰劑治療，安慰劑形狀、色澤、味道等與四磨湯口服液相同，服用周期、次數(shù)及劑量均與四磨湯口服液相同，兩組患者均治療2周，評(píng)價(jià)治療效果以及檢測血漿P物質(zhì)和胃動(dòng)素水平。結(jié)果 觀察組治療有效率為98.33%，高于對(duì)照組的86.67%（P<0.05）。治療前胃動(dòng)素水平及血漿P物質(zhì)組間對(duì)比無統(tǒng)計(jì)學(xué)意義；治療后兩組血漿P物質(zhì)和胃動(dòng)素水平均升高，并且觀察組上升幅度大于對(duì)照組，差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療過程中對(duì)照組發(fā)生惡心、嘔吐病例4例，發(fā)生率為6.67%；觀察組發(fā)生1例，發(fā)生率為1.67%，差異無統(tǒng)計(jì)學(xué)意義。結(jié)論 四磨湯口服液聯(lián)合常規(guī)治療措施可以明顯提高治療效果，并且可能通過提升血漿P物質(zhì)和胃動(dòng)素水平起作用。

Objective To investigate the clinical effect of Simotang Oral Liquid in the treatment of functional dyspepsia (FD) in children. Methods 120 cases of pediatric FD patients admitted in our hospital from January 2016 to December 2016 were divided into observation group and control group according to the random number table method. Sixty patients in each group were given routine treatment, and the observation group was treated Based on the treatment of oral administration of Simotang Oral Liquid, the control group in the conventional treatment based on the placebo treatment, evaluation of treatment and the detection of plasma substance P and motilin levels. Results The effective rate was 98.33% in the observation group and 86.67% higher than that in the control group (P < 0.05). There was no significant difference between the plasma substance P and the motilin level before treatment. After treatment, the levels of plasma substance P and motilin in the two groups were higher than those in the control group (P < 0.05). In the course of treatment, nausea and vomiting occurred in the control group. The incidence was 6.67%, the observation group occurred in 1 case, the incidence was 1.67%. Conclusion Simotang Oral Liquid combined with conventional treatment can significantly improve the therapeutic effect, and may play a role in improving the plasma substance P and motilin levels.